Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1253-1257

  Werngren, J ^a   Sturegard E ^b   Jureen P ^a   Angeby K ^c   Hoffner, S ^a   Schond T ^d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; PRIORITY JOURNAL; REFERENCE VALUE; WILD TYPE;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84857172767     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05894-11     Document Type: Article

References (30)

1. Angeby KA, et al. 2010. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J. Antimicrob. Chemother. 65:946-952.
2. Barco P, et al. 2006. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J. Antimicrob. Chemother. 58:930-935.
3. Butler WR, Kilburn JO. 1982. Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 16:1106-1109. (Pubitemid 13250675)
4. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 55:4499-4505.
5. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301.
6. Davies AP, Billington OJ, McHugh TD, Mitchison DA, Gillespie SH. 2000. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J. Clin. Microbiol. 38:3686-3688.
7. Dormandy J, et al. 2007. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 131:497-501. (Pubitemid 46280411)
8. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
9. Heifets L. 2002. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:11-12. (Pubitemid 34060127)
10. Heifets L, Sanchez T. 2000. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 38:1498-1501. (Pubitemid 30216679)
11. Hewlett D, Jr, Horn DL, Alfalla C. 1995. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 273:916-917.
12. Jureen P, et al. 2010. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J. Clin. Microbiol. 48:1853-1858.
13. Jureen P, Werngren J, Toro JC, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:1852-1854. (Pubitemid 351614686)
14. Kontos F, et al. 2003. Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiometric Bactec 460TB system. J. Microbiol. Methods 55:331-333. (Pubitemid 37297675)
15. McDermott W, Tompsett R. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70:748-754.
16. Morlock GP, et al. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2291-2295. (Pubitemid 30650870)
17. O'Sullivan DM, McHugh TD, Gillespie SH. 2005. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J. Antimicrob. Chemother. 55:674-679. (Pubitemid 40691845)
18. Pfyffer GE, Palicova F, Rusch-Gerdes S. 2002. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J. Clin. Microbiol. 40:1670-1674. (Pubitemid 34493138)
19. Rodrigues Vde F, et al. 2005. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob. Agents Chemother. 49:444-446.
20. Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother. 32:1002-1004.
21. Schon T, et al. 2011. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 15:502-509.
22. Schon T, et al. 2009. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:786-793.
23. Scorpio A, et al. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543. (Pubitemid 27098400)
24. Sekiguchi J, et al. 2007. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J. Clin. Microbiol. 45:2802-2807. (Pubitemid 47417318)
25. Singh P, et al. 2007. Comparative evaluation of Lowenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:76-80. (Pubitemid 46106409)
26. Syre H, Ovreas K, Grewal HM. 2010. Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay. J. Antimicrob. Chemother. 65:704-712.
27. Wayne LG. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
28. World Health Organization. 2008. The programmatic management of drug-resistant tuberculosis - emergency update 2008. World Health Organization, Geneva, Switzerland.
29. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
30. Zhu M, et al. 2002. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 22:686-695. (Pubitemid 34596476)